Investors Shy Away from Pharmaceutical Chemicals

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-07-02-2004
Volume 28
Issue 7

Despite investors' strong interest in the chemical industry overall, pharmaceutical chemical businesses have not experienced much attention from investors thus far.

External Link - article-103356.pdf

Articles in this issue
i1-143861-1408695852146.jpg
3M Drug Delivery Systems
i1-143960-1408695698259.jpg
AccuRate
July 2004
Characterization of the Performance of Bin Blenders Part 2 of 3: Free-Flowing Mixtures
Investors Shy Away from Pharmaceutical Chemicals
From CGMPs to the Critical Path: FDA Focuses on Innovation, Quality, and Continuous Improvement–Inside and Out
In the Spotlight-July 2004
The LR Method in Critical Areas: Airflow Patterns and the Design of Aseptic Interventions
A Stability Program for the Distribution of Drug Products
Politics Versus Science in Biomedical Research and Development
Recent Videos
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Abzena Expands Analytical Services with GMP Cell-Based Potency Testing in US and UK

Feliza Mirasol
November 22nd 2024
Article

The company has expanded its early and late phase analytical capabilities by including GMP cell-based potency assays at its sites in Cambridge, UK, and San Diego, Calif.

Drug Solutions Podcast: Unlocking the Latest Manufacturing Trends

Drug Solutions Podcast: Unlocking the Latest Manufacturing Trends

Felicity Thomas
July 11th 2023
Podcast

In this episode, Sergey Vlasenko from Agilent chats about bio/pharmaceutical manufacturing trends, with a particular focus on oligonucleotides.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Circio and Certest to Collaborate on LNP Formulations

Feliza Mirasol
November 21st 2024
Article

The companies will collaborate to create and test circVec DNA–LNP formulations for use in potential therapeutic applications.

Drug Solutions Podcast: Examining the State of Biopharma Investment

Drug Solutions Podcast: Examining the State of Biopharma Investment

Grant Playter
June 6th 2023
Podcast

In this episode, Siegfried Schmitt, vice president, Technical at Parexel, discusses the state of biopharma investment in 2023.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

CDMO SEKISUI Expands its CGMP Biopharma Manufacturing Capacity

Feliza Mirasol
November 20th 2024
Article

SEKISUI has used a £15.7 million (US$20.7 million) investment to expand its clinical-grade drug substance manufacturing at its UK site.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Alentis Therapeutics to Advance Anti-Claudin-1 ADCs to Treat Solid Tumors on $181.4 Million Financing

Feliza Mirasol
November 19th 2024
Article

Financing from OrbiMed, Novo Holdings, Jeito Capital, and others will enable Alentis Therapeutics to advance its pipeline of Claudin-1-targeted ADCs for treating solid tumors.